|
Developed by 
|
Supported by 
|
Bictegravir (BIC)
Developer(s)
|
Drug structure
Bictegravir chemical structure
MedChemExpress
Drug information
Associated long-acting platforms
Oral solid form
Administration route
Oral
Therapeutic area(s)
Use case(s)
Use of drug
Ease of administration
Frequency of administration
User acceptance
Not provided
Dosage
Available dose and strength
various fixed dose combinations
Maximum dose
Not provided
Recommended dosing regimen
Not provided
Additional comments
Not provided
Drug information
Drug's link(s)
Not provided
Generic name
Brand name
Compound type
Drug class/category
Summary
Approval status
Regulatory authorities
Delivery device(s)
No delivery device
Scale-up and manufacturing prospects
Scale-up prospects
Not provided
Tentative equipment list for manufacturing
Not provided
Manufacturing
Not provided
Specific analytical instrument required for characterization of formulation
Not provided
Clinical trials
Not providedExcipients
Proprietary excipients used
No proprietary excipient used
Novel excipients or existing excipients at a concentration above Inactive Ingredients Database (IID) for the specified route of administration
No novel excipient or existing excipient used
Residual solvents used
No residual solvent used
Patent info
Compound patent families
Patent informations
| Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
|---|---|---|---|---|---|
|
Bictegravir sodium
Expiry date: 2035-06-19 The present Invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10 -((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate Form I. |
WO2015196116 | Compound | Gilead Sciences Inc | No |
Patent status
| Patent status/countries | Low, Low- middle and upper-middle | High income |
|---|---|---|
| Granted | Argentina, China, Cuba, Dominican Republic, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, North Macedonia, Bosnia and Herzegovina, Montenegro, Moldova, Republic of, Mexico, Peru, Philippines, El Salvador, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Comoros, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Bolivia (Plurinational State of), Brazil, Colombia, Malaysia, Nigeria, Pakistan, South Africa, Ukraine | Canada, Australia, Israel, Japan, Korea, Republic of, Singapore, Taiwan, Province of China, United States of America, Chile, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Malta, Norway, Romania, Latvia, Lithuania, Slovenia, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates, Panama, Trinidad and Tobago, New Zealand, Bahamas, Hong Kong, Macao |
| Filed | Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia | Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia, Hong Kong |
| Not in force | World Intellectual Property Organization (WIPO), China, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Morocco, Moldova, Republic of, India, Botswana, Gambia (the), Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Liberia, Rwanda, Sao Tome and Principe, Sudan, Eswatini, Tanzania, United Republic of, Zambia, Zimbabwe, Ecuador, Egypt, Guatemala, Indonesia, Paraguay, South Africa, Venezuela (Bolivarian Republic of), Viet Nam, Thailand | Japan, United States of America, World Intellectual Property Organization (WIPO), Costa Rica, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia, Uruguay, New Zealand, Hong Kong |
Patent informations
| Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
|---|---|---|---|---|---|
|
Bictegravir synthesis
Expiry date: 2035-06-16 Methods of making compounds of Formula (I) are disclosed. |
WO2015195656 | Process | Gilead Sciences, Inc | No |
Patent status
| Patent status/countries | Low, Low- middle and upper-middle | High income |
|---|---|---|
| Granted | Argentina, China, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, Montenegro, Mexico, Brazil, India | Canada, Australia, Israel, Japan, Korea, Republic of, Singapore, Taiwan, Province of China, United States of America, Russian Federation, Belgium, Germany, France, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Portugal, Ireland, Czechia, Slovakia, Hungary, Poland, Norway, Slovenia, New Zealand, Hong Kong, Macao |
| Filed | Argentina | Singapore, United States of America, Bahamas, Hong Kong |
| Not in force | World Intellectual Property Organization (WIPO), China, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Morocco, Mexico | Australia, Israel, United States of America, World Intellectual Property Organization (WIPO), Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia |
Patent informations
| Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
|---|---|---|---|---|---|
|
Bictegravir compounds
Expiry date: 2033-12-19 Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, &Zgr;1 and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. |
WO2014100323 | Compound | Gilead Sciences, Inc | No |
Patent status
| Patent status/countries | Low, Low- middle and upper-middle | High income |
|---|---|---|
| Granted | Argentina, Brazil, China, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Moldova, Republic of, Mexico, Peru, Philippines, Botswana, Gambia (the), Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Liberia, Rwanda, Sudan, Eswatini, Tanzania, United Republic of, Uganda, Zambia, Zimbabwe, El Salvador, Ethiopia, Fiji, India, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Comoros, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Colombia, Grenada, Indonesia, Kiribati, Pakistan, Paraguay, Solomon Islands, South Africa, Tuvalu, Ukraine, Viet Nam, Malaysia, Saint Lucia | Canada, Australia, Hong Kong, Israel, Japan, Korea, Republic of, New Zealand, Singapore, United States of America, Chile, Costa Rica, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, Croatia, Romania, Latvia, Lithuania, Slovenia, Anguilla, Bermuda, Falkland Islands (Malvinas), Montserrat, Panama, Seychelles, Turks and Caicos Islands, Bahamas, Guyana, Gibraltar, Jersey, Macao, Guernsey |
| Filed | Brazil, China, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Bolivia (Plurinational State of), Ecuador, El Salvador, Congo, democratic Republic of the, Indonesia, Jamaica, Nepal, Thailand, Venezuela (Bolivarian Republic of) | Canada, Australia, Israel, Japan, Taiwan, Province of China, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates |
| Not in force | World Intellectual Property Organization (WIPO), Argentina, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, North Macedonia, Albania, Bosnia and Herzegovina, Serbia, Moldova, Republic of, Mexico, Philippines, Uganda, Egypt | Israel, Japan, Korea, Republic of, United States of America, World Intellectual Property Organization (WIPO), Costa Rica, Russian Federation, Spain, Monaco, Malta, San Marino, Uruguay |
Supporting material
Publications
There are no publication
Additional documents
No documents were uploaded
Useful links
There are no additional links
Access principles
|
Collaborate for developmentConsider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology Not provided |
|
Share technical information for match-making assessmentProvide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit Not provided |
|
Work with MPP to expand access in LMICsIn the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing Not provided |
Comment & Information
Not provided